Advertisement

Antihypertensiva

  • E. Hackenthal
Part of the Springer-Lehrbuch book series (SLB)

Zusammenfassung

Anatomisch und funktionell wird der Kreislauf unterteilt in das Kapazitätssystem (venöse Gefäße) und das Widerstandssystem (arterielle Gefäße). Im venösen Kapazitätssystem findet die Volumenregulation des Blutkreislaufes statt. Der Druck ist gering und abhängig von den hydrostatischen Gegebenheiten (zentraler Venendruck ca. 3–6 mmHg). Im Widerstandssystem wird der arterielle Blutdruck durch die Pumparbeit des Herzens aufgebaut. Ein erheblicher Teil dieser Pumparbeit wird in die elastische Dehnung der großen Arterien überführt, die einen stetigen Blutfluß in die Peripherie auch während der Diastole ermöglicht (Windkesselfunktion). Die Höhe des Blutdruckes hängt ab
  1. 1)

    von der Arbeit des Herzens (Druck · Volumen),

     
  2. 2)

    dem Tonus der Widerstandsgefäße und

     
  3. 3)

    dem Füllungszustand des Systems.

     

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Amery A, Fagard R, Lijnen P, Staessen J, Van Hoof R (1990) Treatment of the elderly hypertensive patient. J Hypertens 8 [Suppl 2]):S39–S47CrossRefGoogle Scholar
  2. Anderson S, Rennke HG, Brenner BM (1986) Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 77:1993–2000PubMedCrossRefGoogle Scholar
  3. Bakris GL, Barnhill BW, Sadler R (1992) Treatment of arterial hypertension in diabetic humans: Importance of therapeutic selection. Kidney Int 41:912–919PubMedCrossRefGoogle Scholar
  4. Bauer JH, Reams GP (1995) The angiotensin II type 1 receptor antagonists: A new class of antihypertensive drugs. Arch Intern Med 155:1361–1368PubMedCrossRefGoogle Scholar
  5. Bauer JH, Reams GP, Hewett J (1992) A randomized double-blind, placebo-controlled trial to evaluate the effect of enalapril in patients with clinical diabetic nephropathy. Am J Kidney Dis 20:443–457PubMedGoogle Scholar
  6. Beers MH, Passman LJ (1990) Antihypertensive medications and depression. Drugs 40:792–799PubMedCrossRefGoogle Scholar
  7. Behandlung hypertensiver Krisen (1994) Arzneimittelbrief 28:41–44Google Scholar
  8. Bönner G, Rahn KH (1994) ACE-Hemmer-Handbuch, 2. Aufl. Schattauer, StuttgartGoogle Scholar
  9. Cohen RA (1993) Pathways controlling healthy and diseased arterial smooth muscle. Am J Cardiol 72:39C–47CPubMedCrossRefGoogle Scholar
  10. Collins R, Peto R, MacMahon S et al. (1990) Blood pressure, stroke and coronary heart disease. Part 2. Short term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context. Lancet 335:827–838PubMedCrossRefGoogle Scholar
  11. Corvol P, Jeunemaitre X, Charru A, Soubrier F (1992) Can the genetic factors influence the treatment of systemic hypertension? The case of the renin-angiotensin-Aldosterone system. Am J Cardiol 70:14D–20DPubMedCrossRefGoogle Scholar
  12. Dahlof B, Pennert K, Hansson L (1992) Reversal of left ventricular hypertrophy in hypertensive patients: a meta-analysis of 109 treatment studies. Am J Hypertens 5:95–110PubMedGoogle Scholar
  13. Davey-Smith G, Egger M (1994) Who benefits from medical intervention? Treating low risk patients can be a high risk strategy. BMJ 308:72–74CrossRefGoogle Scholar
  14. Deutsche Liga zur Bekämpfung des hohen Blutdruckes e.V., Heidelberg (1993) Empfehlungen zur Hochdruckbehandlung in der Praxis und zur Behandlung hypertensiver Notfälle. Med Monatsschr Pharmacol 16:321–324Google Scholar
  15. Dusing R (1996) Hemmung des Angiotensin-Typ 1-Rezeptors bei Hypertonie. Arzneimitteltherapie 14:103–107Google Scholar
  16. Duval N, Hicks PE, Langer SZ (1986) Reserpine-resistant responses to nerve stimulation in the cat nictitating membrane involve the release of newly synthesized noradrenaline. Eur J Pharmacol 122:93–101PubMedCrossRefGoogle Scholar
  17. Elving LD, Wetzels JFM, Van-Lier HJJ, et al. (1994) Captopril and atenolol are equally effective in retarding progression of diabetic nephropathy. Diabetologie 37:604–609CrossRefGoogle Scholar
  18. Emeriau JP (1989) Guidelines for treating hypertension in the elderly. Drugs 38:612–620PubMedCrossRefGoogle Scholar
  19. Ernsberger P, Damon TH, Graff LM, Schafer SG, Christen MO (1993) Moxonidine, a centrally acting antihypertensive agent, is a selective ligand for I1-imidazoline sites. J Pharmacol Exp Ther 264:172–182PubMedGoogle Scholar
  20. Ernsberger P, Haxhiu MA, Graff et al. (1994) A novel mechanism of action for hypertension control: moxonidine as a selective I1-imidazoline agonist. Cardiovasc Drugs Ther 8 [Suppl 1]:27–41PubMedCrossRefGoogle Scholar
  21. Freedman DD, Waters DD (1987) „Second generation“dihydropyridine calcium antagonists. Drugs 34:578–598PubMedCrossRefGoogle Scholar
  22. Fuller JH (1993) Hypertension and diabetes: epidemiologic aspects as a guide to management. J Cardiovasc Pharmacol 21 [Suppl 2]:S63–S66PubMedGoogle Scholar
  23. Fulton B, Wagstaff AJ, Sorkin EM (1995) Doxazosin. Drugs 49:295–320Google Scholar
  24. Ganten D, Ritz E (Hrsg)(1985) Lehrbuch der Hypertonic Schattauer, StuttgartGoogle Scholar
  25. Hamilton CA (1992) The role of imidazoline receptors in blood pressure regulation. Pharmacol Ther 54:231–248PubMedCrossRefGoogle Scholar
  26. Hieble JP, Kolpak DC (1993) Mediation of the hypotensive action of systemic Clonidine in the rat by alpha 2-adrenocep-tors. Br J Pharmacol 110:1635–1639PubMedGoogle Scholar
  27. Intersalt Cooperative Research Group (1988) Intersalt: an international study of electrolyte excretion and blood pressure. Results for 24 hour urinary sodium and potassium excretion. BMJ 297:319–328CrossRefGoogle Scholar
  28. Jover B, Mimran A (1994) Angiotensin II receptor antagonists versus angiotensin converting enzyme inhibitors: effects on renal function. J Hypertens 12 [Suppl 9]:S3–S9Google Scholar
  29. Julius S, Jamerson K, Mejia A, Krause L, Schork N, Jones K (1990) The association of borderline hypertension with target organ changes and higher coronary risk. JAMA 254:354–358CrossRefGoogle Scholar
  30. Klaus D (1993) Stellenwert der Diuretika in der Monotherapie der Hypertonie. Fortschr Med 111:304–308PubMedGoogle Scholar
  31. Lantry HD, Mammen GJ, Sorkin EM (1989) Urapidil. Drugs 38:900–940CrossRefGoogle Scholar
  32. Law MR, Frost CD, Wald NJ (1991) Dietary salt and blood pressure. J Hypertens 9 [Suppl 6] 1537–541CrossRefGoogle Scholar
  33. Li G, Regunathan S, Barrow CJ, Eshraghi J, Cooper R, Reis DJ (1994) Agmatine: an endogenous clonidine-displacing substance in the brain. Science 263:966–969PubMedCrossRefGoogle Scholar
  34. Ludwig M, Stumpe KO, Heagerty AM et al. (1993) Vascular wall thickness in hypertension: the perindopril regression of vascular thickening European Community Trial (PROTECT). J Hypertens 11 [Suppl 51:5316–5317Google Scholar
  35. Luke RG (1993) Essential hypertension: a renal disease? Hypertension 21:380–390PubMedGoogle Scholar
  36. MacMahon S, Peto R, Cutler J et al. (1990) Blood pressure, stroke and coronary heart disease. Part 1. Prolonged differences in blood pressure: Prospective observational studies corrected for the regression dilution bias. Lancet 335:765–774PubMedCrossRefGoogle Scholar
  37. Mancia G, van Zwieten PA (1996) How safe are calcium antagonists in hypertension and coronary heart disease. J Hypertens 14:13–17PubMedGoogle Scholar
  38. Mandai AK, Markert RJ, Saklayen MG, Mankus RA, Yokokawa K (1994) Diuretics potentiate angiotensin converting enzyme inhibitor-induced acute renal failure. Clin Nephrol 42:170–174Google Scholar
  39. McAreavey D, Robertson JIS (1990) Angiotensin converting enzyme inhibitors and moderate hypertension. Drugs 40:326–345PubMedCrossRefGoogle Scholar
  40. McInnes GT (1994) Role of ACE inhibitors in hypertension complicated by vascular disease. Br Heart J 72 [Suppl]:33–37CrossRefGoogle Scholar
  41. Meng H, Loew D (1974) Diuretika. Thieme, StuttgartGoogle Scholar
  42. Miller K (1994) Pharmacological management of hypertension in paediatric patients. Drugs 48:868–887PubMedCrossRefGoogle Scholar
  43. Molderings GJ (1995) Imidazolrezeptoren. Arzneimitteltherapie 13:344–350Google Scholar
  44. Mombouli JV, Vanhoutte PM (1995) Kinins and endothelial control of vascular smooth muscle. Ann Rev Pharmacol Toxicol 35:679–705CrossRefGoogle Scholar
  45. Moser M (1990) Antihypertensive medications: relative effectiveness and adverse reactions. J Hypertens 8 [Suppl 2]: S9–S16CrossRefGoogle Scholar
  46. Pinkney JH, Yudkin JS (1994) Antihypertensive drugs: issues beyond blood pressure control. Prog Cardiovasc Dis 36:397–415PubMedCrossRefGoogle Scholar
  47. Praktische Aspekte der Therapie mit Angiotensinkonversionsenzym (ACE)-Hemmern (1994) Arzneimittelbrief 28:25–29Google Scholar
  48. Raine AEG (1994) Hypertension and the kidney. Br Med Bull 50:322–341PubMedGoogle Scholar
  49. Rappelli A, Baldinelli A, Zingaretti O, Espinosa E, Salvi S, Fulgheri PD (1991) The effects of antihypertensive therapy on renal function. J Hypertens 9 [Suppl 3]:S37–S40Google Scholar
  50. Regunathan S, Reis DJ (1996) Imidazoline receptors and their endogenous ligands. Ann Rev. Pharmacol Toxicol 36:511–544CrossRefGoogle Scholar
  51. Richards AM, Nicholls MG, Crozier IG (1994) Role of ACE inhibitors in hypertension with left ventricular hypertrophy. Br Heart J 72 [Suppl]:24–32CrossRefGoogle Scholar
  52. Robertson JIS (1994) Role of ACE inhibitors in uncomplicated essential hypertension. Br Heart J 72 [Suppl]:15–23CrossRefGoogle Scholar
  53. Salvetti A, Brogi G, Di Legge V, Bornini GP (1993) The interrelationship between insulin resistance and hypertension. Drugs 46 [Suppl 2]:149–159PubMedCrossRefGoogle Scholar
  54. Samani NJ (1994) Molecular genetics of susceptibility to the development of hypertension. Br Med Bull 50:260–271PubMedGoogle Scholar
  55. Schmieder RE, Gatzka C, Schächinger H, Schobel H, Rüddel H (1993) Obesity as a determinant for response to antihypertensive treatment. BMJ 307:537–540PubMedCrossRefGoogle Scholar
  56. Streeten DHP, Anderson GH (1992) Secondary hypertension. Drugs 43:805–819PubMedCrossRefGoogle Scholar
  57. Swales JD (ed)(1995) Manual of hypertension. Blackwell, OxfordGoogle Scholar
  58. Taddei S, Salvetti A (1992) Vascular tissue renin-angiotensin system in hypertensive humans. J Hypertens 10 [Suppl 7]: S165–S172CrossRefGoogle Scholar
  59. Ummenhofer C, Kluthe R (1994) Definition von „Salzsensitivität“. Dtsch Med Wochenschr 119:49–57PubMedCrossRefGoogle Scholar
  60. Weichenhain B, van Kooten HJ, Standi E (1993) Hypertension and insulin resistance: Glycaemia and insulinaemia in overweight hypertensive patients. Drugs 46 [Suppl 2]: 183–188PubMedCrossRefGoogle Scholar
  61. Weinberger MH (1996) Salt sensitivity of blood pressure in humans. Hypertension 27:481–490PubMedGoogle Scholar
  62. Wiemer G, Schölkens BA, Linz W (1994) Endothelial protection by converting enzyme inhibitors. Cardiovasc Res 28:166–172PubMedCrossRefGoogle Scholar
  63. Zwieten PA van (1993) An overview of the pharmacodynamic properties and therapeutic potential of combined α- and β-adrenoceptor antagonists. Drugs 45:509–517PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1999

Authors and Affiliations

  • E. Hackenthal

There are no affiliations available

Personalised recommendations